

RECEIVED
CENTRAL FAX CENTER

DEC 09 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	McGee et al.	Confirmation No.:	1490
Serial No.:	10/719,917 ^{997 PP}	Art Unit:	1625
Filed:	November 20, 2003	Examiner:	Seaman, D. Margaret
For:	Quinoliny and Benzothiazoly Modulators	Attorney Docket No.:	018781-006330US (T00-014-3US)

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants have carefully considered the Office Action dated June 15, 2005, in connection with the above-identified patent application. In response, Applicants respectfully request reconsideration of the present application in view of the amendments and remarks that follow.

In this paper, an Amendment to the Specification is presented on page 2, while the remarks begin on page 3.

Applicants file herewith:

1. A Petition for Extension of Time under 37 CFR § 1.136, extending the time for response for a period of three (3) months from September 15, 2005, to December 15, 2005.
2. A Statement under 35 U.S.C. § 103(c)(2) executed by Amgen Inc.
3. A Statement under 35 U.S.C. § 103(c)(2) executed by Japan Tobacco, Inc.

12/12/2005 TL0111 00000058 010519 10719997
01 FC:1253 1020.00 DA